Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience

Authors:
Open Access
Publisher website
Google Scholar
Abstract
The significance of combination of docetaxel (DTX) with estramustine phosphate (EMP) in castration-resistant prostate cancer (CRPC) patients remains unclear. In this study, we aimed to retrospectively evaluate the efficacy and toxicity of DTX with or without EMP and to elucidate the significance of DTX and EMP combination therapy in Japanese EMP-refractory CRPC patients.

This publication has 25 references indexed in Scilit: